May 23, 2023 07:00 PM Eastern Daylight Time HAWTHORNE, N.Y.--( BUSINESS WIRE )--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023. Quarter ended March 31, 2023* Highlights ─ compared to
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jan. 24, 2023-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2022 . Quarter ended December 31, 2022 * Highlights ─ compared to December 31,
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jan. 19, 2023-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022 , after the close of market on Tuesday, January 24, 2023 .
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Oct. 27, 2022-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2022 . Quarter ended September 30, 2022 * Highlights ─ compared to September
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Oct. 24, 2022-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022 , after the close of market on Thursday, October 27, 2022 .
BRAMPTON, Ontario --(BUSINESS WIRE)--Aug. 11, 2022-- Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL vials. The reason for the recall is that product from these lots may contain
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jul. 27, 2022-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2022 . Quarter ended June 30, 2022 * Highlights ─ compared to June 30, 2021 Net sales increased
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jul. 26, 2022-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2022 , filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jul. 26, 2022-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022 , after the close of market on Wednesday, July 27, 2022 .
Alerts are e-mailed to you whenever certain new company information is posted to this site.
